GANX

Gain Therapeutics Stock Analysis

AI Rating

Fair
  • Quality1/10
  • Growth↑ 7/10
  • Momentum↓ 3/10
Gain Therapeutics sales and earnings growth
GANX Growth
Good
  • Revenue Y/Y↓ 0.00%
  • EPS Y/Y↑ 44.55%
  • FCF Y/Y↑ 18.00%
Gain Therapeutics gross and profit margin trends
GANX Profitability
Low
  • Gross margin ↓ 0.00%
  • EPS margin↓ 0.00%
  • ROIC↑ 1085.50%
Gain Therapeutics net debt vs free cash flow
GANX Risk
Great
  • Debt / Equity↓ 0.1
  • Debt / FCF↓ 0.0
  • Interest coverage↓ NA

Gain Therapeutics stock volatility is in-line with the overall market. We give it a Great risk rating.

More Biotechnology stocks ↗